<DOC>
	<DOCNO>NCT02580656</DOCNO>
	<brief_summary>Survival rate cancer continue improve , 2 million adult cancer survivor United Kingdom , project increase 4 million 2030 . Around 25 % survivor require treatment clinical level emotional distress . The investigator conduct phase I open trial test potential efficacy MCT cancer survivor .</brief_summary>
	<brief_title>An Open Trial Metacognitive Therapy Anxiety Depression Cancer</brief_title>
	<detailed_description>Survival rate cancer continue improve , 2 million adult cancer survivor United Kingdom , project increase 4 million 2030 . Around 25 % survivor require treatment clinical level emotional distress . There scope improvement efficacy current pharmacological psychological intervention . Reflecting limited efficacy face need psychological treatment , National Cancer Survivorship Research Initiative highlight development evaluation practically feasible intervention depression anxiety cancer survivor urgent research priority . It recognise current influential psychotherapeutic approach need modify meet specific need associated cancer . However modification pragmatic rather theory-driven improve efficacy . This study address stage 'development ' 'piloting feasibility ' intervention development , albeit relatively well-defined start point give exist evidence efficacy MCT setting promise preliminary evidence applicability cancer . The investigator conduct phase I open trial test potential efficacy MCT cancer survivor .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Cancer diagnosis least 6 month previously Scoring &gt; 15 Hospital Anxiety Depression Scale Total Stable , free , psychotropic medication History psychotic disorder , learn disability , organic mental disorder Risk selfharm suicide warrant immediate intervention In palliative phase treatment Being consider riskreducing reconstructive surgery within 1 year Concurrent psychological treatment Cognitive impairment preclude informed consent participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>